Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.

Saved in:
Bibliographic Details
Title: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.
Authors: Muijs CT; Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium., Berbee M; Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium., van Rossum PSN; Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium., Mohammad NH; Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium., Wijnhoven B; Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium., Van Laarhoven HWM; Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium., Haustermans KM; Christina T. Muijs, MD, PhD, Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands, Maaike Berbee, MD, PhD, Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands, Peter S.N. van Rossum, MD, PhD, Department of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands, Nadia Haj Mohammad, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Bas Wijnhoven, MD, PhD, Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands, Hanneke W.M. Van Laarhoven, MD, PhD, Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands, Karin M. Haustermans, MD, PhD, Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 May 20; Vol. 44 (15), pp. 1465-1467. Date of Electronic Publication: 2026 Mar 05.
Publication Type: Letter
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO-25-01809